Zobrazeno 1 - 10
of 172
pro vyhledávání: ''
Autor:
Nancy L. Bartlett, Felicia Gomez, Matthew Mosior, Malachi Griffith, Anne Fischer, Michelle Becker-Hapak, Mark P. Foster, Melissa M. Berrien-Elliott, Alina D. Schmidt, Marcus Watkins, Amanda F. Cashen, Kilannin Krysiak, Kami J. Maddocks, Nina D. Wagner-Johnston, Jingqin Luo, Obi L. Griffith, Zachary L. Skidmore, Todd A. Fehniger, Sweta Desai, Jeffrey P. Ward
Publikováno v:
Blood
New therapies are needed for patients with relapsed/refractory (rel/ref) diffuse large B-cell lymphoma (DLBCL) who do not benefit from or are ineligible for stem cell transplant and chimeric antigen receptor therapy. The CD30-targeted, antibody-drug
Autor:
R. Spencer Tong, Robert B. Gerbing, Todd A. Alonzo, Jeffrey W. Taub, Jim Wang, Lisa Eidenschink Brodersen, Reuven J. Schore, Maureen M. O'Brien, Amy Heerema-McKenney, Jason N. Berman, Shelton A Viola, Michael R. Loken, E. Anders Kolb, Betsy A. Hirsch, Alan S. Gamis, Karen M. Chisholm, Susana C. Raimondi, Nobuko Hijiya, Amy Beckman, Johann Hitzler, Todd E. Druley
Publikováno v:
Blood. 138:2337-2346
Myeloid leukemia in children with Down syndrome (ML-DS) is associated with young age and somatic GATA1 mutations. Because of high event-free survival (EFS) and hypersensitivity of the leukemic blasts to chemotherapy, the prior Children’s Oncology G
Autor:
Michel Attal, Xavier Leleu, Salomon Manier, Lotfi Benboubker, Clara Mariette, Cécile Sonntag, Karim Belhadj, Denis Caillot, Cyrille Touzeau, Martine Escoffre-Barbe, Benjamin Hebraud, Laurent Garderet, Soraya Wuilleme, Philippe Moreau, Jill Corre, Valérie Lauwers-Cances, Thierry Facon, Jehan Dupuis, Murielle Roussel
Publikováno v:
Blood. 138:113-121
Bortezomib, lenalidomide, and dexamethasone plus transplant is a standard of care for eligible patients with multiple myeloma. Because responses can deepen with time, regimens with longer and more potent induction/consolidation phases are needed. In
Autor:
Anneke C.J. Ammerlaan, Ying Chen, Franco Locatelli, Christian M. Zwaan, Cristina Díaz-de-Heredia, Benoit Brethon, Christiane Chen-Santel, Ingrid Øra, Monique L. den Boer, Barbara Sleight, Bella Bielorai, Andrea Malone, Claudia Rossig, Marta Lopez-Yurda, Vincent H.J. van der Velden, Adriana Thano, Erica Brivio, Lucie Sramkova, Luciana Vinti, Inge M. van der Sluis, Karsten Nysom
Publikováno v:
Blood, 137(12), 1582-1590. American Society of Hematology
Blood
Blood
This phase 1 study investigated the recommended phase 2 dose (RP2D) of inotuzumab ozogamicin (InO), a CD22-directed antibody-drug conjugate, in pediatric patients with multiple relapsed/refractory (R/R) CD22+ acute lymphoblastic leukemia (ALL). Patie
Autor:
J. Mark Sloan, Shayna Sarosiek, Anthony C Shelton, Ramon Cruz, Amanda Schulman, Mary Ellen Migre, Vaishali Sanchorawala, Dina Brauneis, Meredith Mistark
Publikováno v:
Blood
Daratumumab, a monoclonal CD38 antibody, is approved in the treatment of myeloma, but its efficacy and safety in light-chain (AL) amyloidosis has not been formally studied. This prospective phase 2 trial of daratumumab monotherapy for the treatment o
Autor:
Erik Eckhert, Surbhi Sidana, Sally Arai, Alfred Chung, Gregory P. Kaufman, Richard A. Lafayette, Michaela Liedtke, Stanley L. Schrier, Ronald M. Witteles
Publikováno v:
Blood Advances. 4:458-466
Immunoglobulin light chain amyloidosis (AL amyloidosis) involves deposition of abnormally folded light chains into a wide range of tissues causing organ dysfunction, including in the heart and kidney. Daratumumab, a CD38-targeted antibody, has recent
Autor:
Karl S. Peggs, Stephen Mackinnon, Irfan Kayani, Emma Das-Gupta, Anthony Lawrie, Nadjet El-Mehidi, Andrew Clark, David C. Linch, Amy A Kirkwood, Adrian Bloor, Kirsty Thomson, Pip Patrick, Nigel H. Russell, Laura Clifton-Hadley
Publikováno v:
Blood Advances. 3:4264-4270
We evaluated the role of allogeneic hematopoietic stem cell transplantation (allo-HSCT) in transplant-naïve patients with relapsed/refractory Hodgkin lymphoma (HL) who failed to attain metabolic complete response (mCR) to 1 to 2 lines of salvage che
Autor:
Rebeca Bailén, José Luis Díez-Martín, Pascual Balsalobre, David P. Serrano, Ismael Buño, Nieves Dorado, Laura Solán, Maria Jesus Pascual-Cascon, Carolina Martínez-Laperche, Abel García Sola, Ana Isabel Gallardo-Morillo, Mi Kwon, Javier Anguita, Cristina Muñoz
Publikováno v:
Blood Advances. 3:3351-3359
Posttransplant cyclophosphamide (PTCy) effectively prevents graft-versus-host disease (GVHD) after HLA-haploidentical hematopoietic stem cell transplantation (HSCT). The use of PTCy in HLA-identical HSCT is less explored. We conducted a retrospective
Autor:
Christopher C. Dvorak, James Gajewski, Amer Beitinjaneh, Jaap Jan Boelens, David Gómez-Almaguer, Miguel Angel Diaz, Usama Gergis, Hillard M. Lazarus, Mahmoud Aljurf, Joseph H. Antin, Michael A. Pulsipher, Paul J. Orchard, Jean A. Yared, Soyoung Kim, Marta González Vicent, Hisham Abdel-Azim, Kyle Hebert, Andrew R. Gennery, Bipin N. Savani, Ann E. Woolfrey, Biju George, Hasan Hashem, Blachy J. Dávila Saldaña, Kimberly A. Kasow, Natasha Kekre, Olle Ringdén, Daniel J. Weisdorf, Rammurti T. Kamble, Vikram Mathews, Sherif M. Badawy, Kirk R. Schultz, Robert Peter Gale, Siddhartha Ganguly, Mary Eapen, Shahinaz M. Gadalla, Jacek Winiarski, Ibrahim Ahmed, Nelli Bejanyan, Pierre Teira
Publikováno v:
Blood advances, vol 3, iss 20
Allogeneic bone marrow transplantation (BMT) is curative therapy for the treatment of patients with severe aplastic anemia (SAA). However, several conditioning regimens can be used for BMT. We evaluated transplant conditioning regimens for BMT in SAA
Autor:
Joseph P. McGuirk, Ran Reshef, Michael R. Grunwald, Mary Eapen, Natasha Kekre, Rizwan Romee, Ephraim J. Fuchs, Christopher G. Kanakry, Mahasweta Gooptu, Robert J. Soiffer, Claudio G. Brunstein, Nilanjan Ghosh, Mark A. Schroeder, Saurabh Chhabra, Yoshihiro Inamoto, Ian McNiece, Filippo Milano, Dipenkumar Modi, Rohtesh S. Mehta, Monzr M. Al Malki, Joseph H. Antin, Edmund K. Waller, Marco Mielcarek, Andrew St. Martin, Christopher Bredeson, Scott R. Solomon, Mukta Arora
Publikováno v:
Blood
Post transplant cyclophosphamide (PTCy) graft-versus-host disease (GVHD) prophylaxis has allowed haploidentical (Haplo) transplantation to be performed with results similar to that after matched unrelated donor (MUD) transplantation with traditional